https://pharmoniq.com/news/genmab-petosemtamab-head-neck-cancer-phase-3-death-risk-50 PharmoniQ en 2026-10-31T08:05:53.637Z Genmab Combo Lowers Death Risk 50% in Advanced Head and Neck Cancer Genmab, petosemtamab, head and neck cancer, phase 3, oncology https://pharmoniq.com/news/lenz-therapeutics-cuts-75-percent-staff-ceo-steps-down PharmoniQ en 2026-10-30T14:05:45.694Z LENZ to Cut About 75% of Staff as Its CEO Steps Down LENZ Therapeutics, layoffs, presbyopia, ophthalmology, restructuring https://pharmoniq.com/news/fda-expands-pfizer-talzenna-xtandi-earlier-prostate-cancer PharmoniQ en 2026-10-30T08:06:37.810Z FDA Widens Talzenna Label After 52% Cut in Progression or Death Risk Pfizer, FDA approval, prostate cancer, oncology, Astellas https://pharmoniq.com/news/molecular-partners-cuts-up-to-44-percent-of-staff-radiotherapy-pivot PharmoniQ en 2026-10-29T14:10:30.567Z Molecular Partners to Cut Up to 44% of Staff in Radiotherapy Pivot Molecular Partners, layoffs, radiopharmaceuticals, Orano Med, small cell lung cancer